evidoria

← Back to browse

Good practice Imported

UniQuest — University of Queensland's Commercialisation Company

Australia · Brisbane · See the Australia profile · See the Brisbane profile

Evidence: Descriptive / self-reported Top 42% 71/100 · Ask Evidence Copilot about this practice

UniQuest, UQ's commercialisation company since 1984, has produced 360+ US patents and 130+ start-ups (Gardasil, Spinifex, Inflazome); in July 2025 Sanofi agreed to acquire its spin-out Vicebio for up to US$1.6bn — Australia's largest-ever university IP deal.

360+
US patents granted (1984–present)
130+
Start-up companies formed (1984–present)
AUD$1 billion+
Funds raised by spin-outs
AUD$86 billion+
Cumulative product sales
US$1.15 billion upfront + up to US$450 million in milestones (up to US$1.6 billion total)
Vicebio acquisition value (announced July 2025)
UniQuest — University of Queensland's Commercialisation Company

Details

Maturity
Established
Promoter
UniQuest Pty Limited (wholly owned by The University of Queensland)
Period
1984–present
Keywords
University technology transfer, biotech/vaccine commercialisation, startup creation

Context

UniQuest is the University of Queensland's wholly owned commercialisation company, established in 1984 to patent, license and spin out research from UQ; a $5 million investment in 1996 helped it grow into one of Australia's largest university technology-transfer operations.

Objectives

UniQuest manages UQ's intellectual-property portfolio, files and prosecutes patents, negotiates licences with industry, and creates and holds equity in spin-out companies built on university research spanning biotech, agtech and engineering.

Activities

Over four decades, UniQuest has been granted more than 360 US patents and formed more than 130 start-up companies from UQ intellectual property, including licensing the HPV vaccine Gardasil to CSL Limited in 1994 and helping spin out Vicebio in 2018 around UQ's Molecular Clamp vaccine-stabilisation technology.

Results

UniQuest's spin-out companies have collectively raised more than AUD$1 billion and generated more than AUD$86 billion in cumulative product sales; in July 2025 Sanofi agreed to acquire Vicebio for up to US$1.6 billion (US$1.15 billion upfront plus up to US$450 million in milestones), independently confirmed as the largest-ever intellectual-property deal from an Australian university.

Conclusions

The Vicebio deal is independently verified by Sanofi's own press release and international wire services, giving it unusually solid third-party confirmation, but the broader historic cumulative sales and fundraising totals remain UniQuest's own self-reported figures.

Implementation
Indicative cost
Medium (€50k–€500k) — An initial $5 million investment in 1996 helped scale the operation; ongoing operating budget is not disclosed in the sources reviewed.
Time to results
Long (> 3 years) — Operating continuously since 1984, with its largest-ever commercial outcome occurring as recently as July 2025.
Staffing & skills
UniQuest Pty Limited, wholly owned by the University of Queensland, staffed to manage IP, licensing and spin-out equity; UQ researchers (e.g. Professors Paul Young, Daniel Watterson and Keith Chappell for Vicebio) originate the underlying technology.

Conditions for success

  • Strong, sustained university research base at UQ
  • A dedicated, long-running commercialisation entity with in-house patenting and licensing capability
  • Willingness to hold and manage equity stakes in spin-out companies over many years

Where it fits

Governance type
wholly-owned university commercialisation company
Scale
single university, international commercial reach
Income level
high-income (Australia)

Commonly funded by

National / regional programmes

Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.

Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.

Data sources

Where this practice's information was retrieved from, and when.

Attachments

Similar practices you may find useful